ArticleKidney medicine2026
Bactrim Efficacy in Preventing Infections in Glomerular Diseases Receiving Rituximab.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: The efficacy of combination sulfamethoxazole and trimethoprim (Bactrim) prophylaxis for infection prevention in kidney disease with rituximab therapy remains unclear. This study investigated its effectiveness in 2 distinct glomerular disease groups treated with rituximab. Study Design: Retrospective cohort study. Setting & Participants: Adults with antineutrophil cytoplasmic antibody-associated vasculitis renal involvement (AAV-R) or renal-limited diseases including membranous nephropathy (MN), minimal change disease (MCD), or primary focal segmental glomerulosclerosis (FSGS) who underwent rituximab therapy between 2012 and 2022 at Mayo Clinic. Exposures: Receiving Bactrim or not. Outcomes: Severe infection during 1-year follow-up after rituximab initiation. Analytical Approach: Kaplan-Meier method used for the probability of survival free of infection. Cox proportional hazards models used for the association between Bactrim use and risk of infection. Results: Among 419 patients, 248 were diagnosed with AAV-R and 171 with MN/MCD/FSGS. During the initial rituximab therapy session, 186 (75%) patients with AAV-R and 76 (44%) with MN/MCD/FSGS were concurrently administered Bactrim. Among those with AAV-R, patients prescribed Bactrim versus without Bactrim were generally younger, with lower serum creatinine, elevated white blood cells and neutrophils, and higher steroid use ( Limitations: Retrospective study. Conclusions: Bactrim prophylaxis could be especially beneficial for reducing infection risk in patients with AAV-R undergoing rituximab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.